Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 19/20 | 0.60 |
| ▸ | FPR3 | P25089 | 1/20 | 0.55 |
| ▸ | GPR65 | Q8IYL9 | 1/20 | 0.55 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.55 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6076982 | 0.86 | CCR1 (0.64) | CCR1FPR3GPR65GPR35PTGDR2 | |
| SCHEMBL6077520 | 0.85 | CCR1 (0.62) | CCR1FPR3GPR65GPR35PTGDR2 | |
| SCHEMBL6077864 | 0.83 | CCR1 (0.60) | CCR1FPR3GPR65GPR35PTGDR2 | |
| SCHEMBL5056171 | 0.80 | CCR1 (0.64) | CCR1FPR3GPR65GPR35PTGDR2 | |
| SCHEMBL6247168 | 0.80 | CCR1 (0.64) | CCR1FPR3GPR65GPR35PTGDR2 | |
| SCHEMBL6076474 | 0.80 | CCR1 (0.64) | CCR1FPR3GPR65GPR35PTGDR2 | |
| SCHEMBL6077669 | 0.80 | CCR1 (0.68) | CCR1FPR3GPR65GPR35PTGDR2 | |
| SCHEMBL6076309 | 0.80 | CCR1 (0.63) | CCR1FPR3GPR65GPR35PTGDR2 | |
| SCHEMBL6250627 | 0.79 | CCR1 (0.62) | CCR1FPR3GPR65GPR35PTGDR2 | |
| SCHEMBL6077208 | 0.79 | CCR1 (0.68) | CCR1FPR3GPR65GPR35PTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040092529-A1 | Methods of using piperazine derivatives | PFIZER INC | 2004-05-13 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040092529-A1 | Methods of using piperazine derivatives | CCR1, CCR3, CCR5 | CCR1 1/4885FPR3 90/4885GPR65 163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.